Producer
Boehringer Ingelheim Animal Health
Boehringer Ingelheim Animal Health (Ingelheim am Rhein, Germany; private; ~€4B animal health revenue) manufactures VECTORMUNE HVT-AI recombinant poultry vaccines using herpesvirus of turkeys (HVT) as a vector. The recombinant platform simultaneously protects against Marek's disease and avian influenza. US manufacturing at Pope Valley CA and Duluth GA. Boehringer Ingelheim is the second-largest animal health company globally.
2
Inputs supplied
1
Goods downstream
2
Facilities
0
Stories
What they make
2 inputs Boehringer Ingelheim Animal Health supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Boehringer Ingelheim Animal Health makes, pick one to see the full supply chain.
Where they make it
2 facilities
Boehringer Ingelheim Animal Health USA Duluth Site (Duluth, Georgia) →
USGeorgia · manufacturing
Boehringer Ingelheim Animal Health USA headquarters and primary North American manufacturing site in Duluth Georgia — formerly the US headquarters of Merial (the Sanofi-Merck animal health joint venture) before Boehringer Ingelheim's $12.5B acquisition of Merial in 2017. Produces Heartgard (ivermectin — parasiticide for dogs but manufactured with GMP applicable to cattle ivermectin products), cattle vaccines, and Metacam (meloxicam NSAID) formulations for the US dairy market. The Duluth campus was built by Merck AgVet (Merck's animal health division) in the 1990s before becoming Merial and then Boehringer Ingelheim — making it a facility with three corporate identities in 25 years. Source: https://www.boehringer-ingelheim.com/animal-health/us-operations
Boehringer Ingelheim Pope Valley CA Poultry Biologics →
USCalifornia · lab
Boehringer Ingelheim's Pope Valley CA facility produces recombinant HVT-vectored poultry vaccines including VECTORMUNE HVT-AI. Specialized live-virus biologics manufacturing for commercial poultry.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Poultry Vaccines & Biologics
32%Companion Animal Parasiticides
28%Cattle & Swine Vaccines
22%Equine & Other Animal Products
18%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Boehringer Ingelheim Animal Health makes NexGard (afoxolaner) — the dominant companion animal flea and tick treatment in the US and Europe, a consumer product associated with pet ownership. The same BI Animal Health also makes the poultry vaccines protecting chickens in industrial broiler and layer operations worldwide. The same R&D, regulatory affairs, and manufacturing infrastructure serves both: the food animal supply chain (vaccines for chickens that become food) and the companion animal market (pharmaceuticals for pets that are treated as family members). The food system supply chain and the pet care supply chain share a single pharma parent — with entirely different customer expectations, price sensitivities, and regulatory scrutiny.
Boehringer Ingelheim ↗Origin2023
Boehringer Ingelheim Animal Health was built through major acquisitions: the 2017 asset swap with Sanofi (BI got Merial animal health, Sanofi got BI's consumer healthcare) and the 2024 acquisition of Elanco's US poultry biologics portfolio for $885M. The Merial acquisition gave BI NexGard (the world's best-selling companion animal parasiticide at the time of acquisition) and Frontline — transforming BI from a livestock vaccine specialist into a dual food animal / companion animal health leader. The combination of Merial's companion animal parasiticides and BI's existing livestock vaccine capabilities made BI the #2 global animal health company after Zoetis.
Boehringer Ingelheim ↗